Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
HOWL 11.20.2024
About Gravity Analytica
Recent News
- 01.13.2025 - Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
- 12.05.2024 - 7th Annual Evercore ISI HealthCONx Healthcare Conference
- 11.20.2024 - Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Recent Filings
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida.
A live webcast link for the Evercore ISI HealthCONx Conference fireside chat will be available athttps://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
AboutWerewolfTherapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINETM molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visitwww.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINETM and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
InvestorContact:John NortonPrecision AQ212.362.1200john.norton@precisionaq.com
MediaContact:Amanda SellersDeerfield Group301.332.5574amanda.sellers@deerfieldgroup.com
CompanyContact:Ellen LubmanChief Business OfficerWerewolf Therapeuticselubman@werewolftx.com
